Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal J Meropol

Showing results (91-100 of 226) with videos related to

Pageof 23
Sort By:
Preventive Medicine|December 11, 2002
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational modelSharon Manne, Arnold Markowitz, Sidney Winawer, et al.
Cancer|August 3, 2007
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerJ Randolph Hecht, Amita Patnaik, Jordan Berlin, et al.
BMC Medical Informatics and Decision Making|April 9, 2014
A simulation model of colorectal cancer surveillance and recurrenceJohnie Rose, Knut Magne Augestad, Chung Yin Kong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
American Society of Clinical Oncology guidance statement: the cost of cancer careNeal J Meropol, Deborah Schrag, Thomas J Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecanLeslie E Carlini, Neal J Meropol, John Bever, et al.
The American Journal of Managed Care|July 27, 2021
ACA Medicaid expansion association with racial disparity reductions in timely cancer treatmentBlythe J S Adamson, Aaron B Cohen, Cary P Gross, et al.
American Journal of Clinical Oncology|April 1, 2008
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumorsSteven J Cohen, Paul F Engstrom, Nancy L Lewis, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2015
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesMargaret von Mehren, Michael Bookman, Neal J Meropol, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2007
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancerSharon L Manne, Daniel C Chung, David S Weinberg, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response RatesEhsan Malek, Caner Saygin, Rebecca Ye, et al.
Pageof 23

Showing results (91-100 of 226) with videos related to

Sort By:
Pageof 23
Preventive Medicine|December 11, 2002
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational modelSharon Manne, Arnold Markowitz, Sidney Winawer, et al.
Cancer|August 3, 2007
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerJ Randolph Hecht, Amita Patnaik, Jordan Berlin, et al.
BMC Medical Informatics and Decision Making|April 9, 2014
A simulation model of colorectal cancer surveillance and recurrenceJohnie Rose, Knut Magne Augestad, Chung Yin Kong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
American Society of Clinical Oncology guidance statement: the cost of cancer careNeal J Meropol, Deborah Schrag, Thomas J Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecanLeslie E Carlini, Neal J Meropol, John Bever, et al.
The American Journal of Managed Care|July 27, 2021
ACA Medicaid expansion association with racial disparity reductions in timely cancer treatmentBlythe J S Adamson, Aaron B Cohen, Cary P Gross, et al.
American Journal of Clinical Oncology|April 1, 2008
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumorsSteven J Cohen, Paul F Engstrom, Nancy L Lewis, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2015
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesMargaret von Mehren, Michael Bookman, Neal J Meropol, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2007
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancerSharon L Manne, Daniel C Chung, David S Weinberg, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response RatesEhsan Malek, Caner Saygin, Rebecca Ye, et al.
Pageof 23